DOCETAXEL

DOCETAXEL ANHYDROUS

Manufacturer: Ingenus Pharmaceuticals, LLC

Score: 145.0

Quick Summary

Docetaxel is an antineoplastic agent used for the treatment of various cancers, including breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. It works by disrupting the microtubular network in cells, leading to inhibition of mitosis and cell death. The recommended dose of Docetaxel varies by indication and is typically administered intravenously every 3 weeks. Important safety information includes the risk of toxic deaths, hepatotoxicity, neutropenia, hypersensitivity reactions, and fluid retention. Contraindications include hypersensitivity to Docetaxel or polysorbate 80, and neutrophil counts of <1500 cells/mm^3. Special population considerations include use in pregnancy, nursing mothers, pediatric patients, and geriatric patients.

Key Clinical Findings and Indications

Breast cancer: locally advanced or metastatic breast cancer after failure of prior chemotherapy
Non-small cell lung cancer: locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy
Prostate cancer: metastatic castration-resistant prostate cancer
Gastric adenocarcinoma: advanced gastric adenocarcinoma
Head and neck cancer: induction treatment of locally advanced squamous cell carcinoma of the head and neck

Important Safety Information

Warning

TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION

Contraindications

Hypersensitivity to Docetaxel or polysorbate 80
Neutrophil counts of <1500 cells/mm^3

Adverse Reactions

Infections
Neutropenia
Anemia
Febrile neutropenia
Hypersensitivity reactions
Thrombocytopenia
Neuropathy
Dysgeusia
Dyspnea
Constipation
Anorexia
Nail disorders
Fluid retention
Asthenia
Pain
Nausea
Diarrhea
Vomiting
Mucositis
Alopecia
Skin reactions
Myalgia

Dosing Recommendations

Nursing Mothers

It is not known whether Docetaxel is excreted in human milk
Use in nursing mothers is not recommended unless the potential benefits outweigh the risks

Pediatric Use

The efficacy and safety of Docetaxel in pediatric patients have not been established
Use in pediatric patients is not recommended unless the potential benefits outweigh the risks

Geriatric Use

Dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy
Elderly patients may be more susceptible to the toxicities of Docetaxel

Similar Drugs

Docetaxel

DOCETAXEL

Gland Pharma Limited

Similarity: 98.1%

Nerlynx

NERATINIB

Puma Biotechnology, Inc.

Similarity: 62.3%

Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)

PACLITAXEL

TWi Pharmaceuticals, Inc.

Similarity: 61.4%